In terms of anti-tumor immunity, EZH2+CD8+ T cells are often void of dysfunction markers (KLRG1, Tim-3, CD57), and the EZH2+CD8+ T cell population positively correlates to anti-tumor response (Wherry, 2011; Crespo et al., 2013; Zhao et al., 2016). This evidence concerns the gene CD8A and neoplasm.